Human immunodeficiency virus type 1 (HIV-1) remains incurable owing to the stability of the latent reservoir in resting memory CD4 + T cells (rCD4 cells) [1] [2] [3] . The latent reservoir consists of stably integrated HIV-1 proviruses that are replication competent but transcriptionally silent. Therefore, these latently infected cells remain undetected by host immune defenses. Although antiretroviral therapy (ART) can prevent the infection of new host cells, it has no effect on latently infected cells. However, latency may be reversed by mechanisms such as immune activation. This potential for reactivation provides a source of virus that results in rebound of viremia on cessation of ART [4] . Although the majority of proviruses contain defects rendering them replication incompetent [5] , intact replication-competent proviruses can be measured in viral outgrowth assays. In Americans infected with clade B HIV-1, the frequency of latently infected cells containing replication-competent provirus is generally on the order of one per one million rCD4 cells [1, [6] [7] [8] [9] [10] [11] [12] . Longitudinal studies carried out using rCD4 cells from patients receiving suppressive ART have demonstrated that this reservoir is incredibly stable, decaying slowly with a half-life of approximately 3.5 years [6, 11, 13] . As a result, it is estimated that suppressive ART alone would require >70 years to clear the latent reservoir, a time frame outside the life expectancy of nearly all individuals living with HIV-1. Understanding what drives both the formation and maintenance of the reservoir may inform strategies to accelerate its decay.
To date, studies characterizing the latent reservoir have focused on North American cohorts. However, 70% of individuals infected with HIV-1 reside in sub-Saharan Africa. Studies of the latent reservoir in Americans have demonstrated that reservoir size correlates positively with pre-ART plasma HIV-1 RNA, including both the duration of infection before ART initiation [7, 8, 11, 14] and also the set-point viral load [7] . After initiation of suppressive ART, reservoir size declines slowly, with a half-life of 44 months [6, 7, 11, 13, 15] . Other contributors to reservoir formation or decay remain incompletely understood. Immune activation reverses HIV-1 latency, resulting in the death and/ or immunologic clearance of infected cells [1] [2] [3] 16] . However, homeostatic proliferation, clonal expansion, CD4 + T-cell depletion, and immune exhaustion may all affect reservoir size and decay rate, even in the setting of suppressive ART [7, 14, [17] [18] [19] [20] [21] . Ugandans are distinct from Americans in terms of lifetime immunologic challenges, HIV-1 subtypes, and genetic background. It is unknown whether Ugandans are similar to Americans in reservoir size and its clinical correlates. To address these questions, we performed an initial observational, cross-sectional study of HIV-1-infected individuals living in Rakai, Uganda, and compared these results with those in a previously studied cohort of HIV-1-infected individuals living in Baltimore, Maryland.
METHODS

Study Participants
Ugandan participants (n = 70) were recruited at the Rakai Health Sciences Program from February to September 2015. Participants were HIV-1-infected adults (aged ≥18 years) receiving ART who had been virally suppressed for >1 year at the time of enrollment (2 plasma HIV-1 RNA levels <40 copies/mL, 10-18 months apart with no intervening detectable result). Historical plasma HIV-1 RNA levels, CD4 + T-cell counts, and ART regimens were available through the Rakai Health Sciences Program. For analysis, 180 mL of blood was collected through venipuncture and separated for T-cell counting, peripheral blood mononuclear cell (PBMC) isolation, and plasma HIV-1 RNA detection. PBMCs were isolated using density centrifugation on a Ficoll-Hypaque gradient and cryopreserved in 10% dimethyl sulfoxide/Roswell Park Memorial Institute 1640 medium. Of note, a recent blinded, multicenter study using paired fresh and previously cryopreserved PBMC samples found that cryopreservation had no impact on quantitative viral outgrowth assay (QVOA) IUPM measurement [22] . Serum RNA was extracted using the Abbott Sample Preparation System and amplified using Real Time HIV-1 Amplification Reagent Kits (Abbott Molecular), and levels were measured using the M2000 Realtime System (Abbott), with a lower limit of detection of 40 copies/mL. T-cell counts were performed using Tritest Reagent with Trucount Tubes and analyzed on a FACSCalibur platform (BD Biosciences).
The frequency of latently infected rCD4 cells in Ugandan participants was compared with available historical data from an American population, which has been published elsewhere [9, 10, 12] . Reservoir measurements (described below) were performed in the same laboratory, using the same method for both populations. American participants (n = 51) were HIV-1-infected adults (aged ≥18 years) attending a large urban HIV clinical practice in Baltimore and had been receiving ART with undetectable plasma HIV-1 RNA levels (<50 copies/mL) for ≥8 months. 
Quantitative Viral Outgrowth Assay Methods
QVOAs on the Ugandan samples were performed in the same laboratory and using the same methods used with American samples [1, 9, 23, 24] . Virus released from latently infected cells after PHA activation was expanded using MOLT-4 cells transfected with CCR5 and naturally expressing CD4 and CXCR4 (MOLT4/CCR5; National Institutes of Health AIDS reagent program). The culture supernatants were examined for presence of actively growing virus using a p24 viral capsid protein enzyme-linked immunosorbent assay (PerkinElmer) after 14-21 days [9] . Supernatants from wells positive for p24 were archived for HIV-1 subtyping. IUPM values were calculated using IUPMStats [25] . If all culture wells were negative for viral outgrowth, the median posterior estimate of infected cell frequency was used (including all analyses and figures). Similar proportions of Ugandan and American participants had undetectable reservoirs (19.4% of Ugandans and 21.4% of Americans; P = .81).
Human Immunodeficiency Virus-1 Subtyping
HIV-1 subtypes for American participants were obtained from previous clinical ART resistance screening, where available. Subtyping for Ugandan participants was performed with next-generation amplicon sequencing of viral RNA, either from wells positive for outgrowth in the QVOA or from pre-ART serum samples, depending on serum availability through the Rakai Community Cohort Study. Viral RNA was extracted from 150 μL of the sample. The viral RNA sequence was obtained by sequencing polymerase chain reaction amplicon fragments using a nested next-generation sequencing assay involving reverse-transcriptase and gp41-targeted primers, as described elsewhere [26] . Subtypes for RT and gp41 were determined phylogenetically or using the National Center for Biotechnology Information HIV subtyping tool (https://www.ncbi.nlm.nih. gov/projects/genotyping/formpage.cgi) if phylogenetic analysis results were unclear. Individuals with both RT and gp41 regions identified as the same subtype were classified with a pure subtype, and those with divergent calls were classified as recombinants.
Statistical Analysis
Demographic and clinical characteristics were compared between Ugandans and Americans using Fisher exact tests for discrete variables and Wilcoxon rank-sum tests for continuous variables. Duration of suppressive ART was defined beginning once plasma HIV-1 RNA became undetectable (<400 copies/ mL) for ≥6 months and ending at the time of study blood sampling. Undetectable viral load for this variable was defined with a cutoff of <400 copies/mL to allow for a consistent definition over time, despite increasing assay sensitivity in later years. Study eligibility (undetectable viral load for >1 year before study participation) was defined using the more stringent cutoff now available (Ugandans, 40 copies/mL; Americans, 50 copies/mL). Some participants experienced instances of transiently detectable viremia (>400 copies/mL) during ART treatment (among Americans [21 of 51 participants]: median detectable viral load, 5334 copies/mL [interquartile range 970-32 539 copies/mL]; among Ugandans [4 of 70]: 1276 copies/mL [798-2035 copies/mL]), which may represent a transient loss of ART suppression and therefore contribute to reservoir reseeding (ART compliance information was not available). These instances are summarized as the proportion of viral load measurements since initial suppression that were >400 copies/mL, to account for increased viral load sampling in Americans compared with Ugandans (3-11 vs 1-2 measurements per year). Note that no participant experienced transiently detectable viremia for ≥1 year before study enrollment and blood sampling.
Log 10 -transformed IUPM measurements generated by the QVOA were used to estimate latent HIV-1 viral reservoir size in Ugandans and Americans. Differences in reservoir size between Ugandans and Americans were estimated using linear regression analysis. Demographics and clinical characteristics that differed (but also overlapped, ie, not including HIV-1 subtype) between Americans and Ugandans (P < .10), were controlled for in the analysis using multivariate regression (including age, sex, HIV exposure risk, pre-ART HIV-1 RNA plasma levels, nadir CD4 + T-cell count, ART regimen, duration of viral suppression, proportion of viral loads >400 copies/mL, and CD4 + T-cell count at study enrollment). Associations between reservoir size and clinical characteristics were assessed using multivariate linear regression, controlling for covariates previously reported in the literature to be associated with reservoir size (pre-ART HIV-1 RNA plasma levels, duration of suppressive ART, and instances of transiently detectable HIV-1 RNA after initial suppression [7, 8, 11, 13, 14] ). Analyses of correlates of reservoir size were performed separately in Ugandans and Americans, and the effect sizes of the associations between clinical characteristics and reservoir size were compared between Americans and Ugandans through the inclusion of an interaction term in regression analyses (for those clinical characteristics found to be significantly associated with reservoir size in at least 1 population, ie, pre-ART HIV-1 RNA plasma levels and duration of suppressive ART). Stata 14 software for Mac was used to conduct statistical analysis and create scatterplots; Prism 5.0 software (GraphPad) was used to construct bar graphs. All tests are 2 sided with an α value of .05.
RESULTS
To determine whether the size of the latent HIV-1 reservoir differed between Ugandans and Americans, we performed a cross-sectional observational study comparing HIV-1 reservoir size between a cohort of Ugandans (n = 70) and historical HIV-1 reservoir data from a population of HIV-infected individuals living in Baltimore (n = 51). Ugandans were younger than Americans (median, 43 vs 51 years), more likely to be female (67% vs 26%), and reported only heterosexual risk of HIV exposure, whereas Americans reported more diverse risk behavior (all P < .001; Table 1 ). Americans with available HIV-1 subtype data (15 of 51) were exclusively infected with HIV-1 subtype B, whereas Ugandans with available subtype data (58 of 70) were infected with subtypes D (69.0%), A (19.0%), or A/D recombinant viral strains (12.1%). Compared with Americans, Ugandans had lower pre-ART plasma HIV-1 RNA levels (viral set point, 45 300 vs 142 800 copies/mL; P = .03; Table 1 ) but similar nadir CD4 + T-cell counts.
Ugandans were almost exclusively receiving an ART regimen consisting of nucleoside reverse-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors, whereas Americans commonly received protease, integrase, and/or entry inhibitors in addition to nucleoside or nonnucleoside reverse-transcriptase inhibitors (Table 1 ; P < .001). Ugandans were less likely than Americans to have instances of detectable plasma HIV-1 RNA (>400 copies/mL) after initial viral suppression (mean proportion of viral loads that were detectable, 0.005 vs 0.037; P < .001; Table 1 ). Although all participants were treated during chronic infection, Ugandans had been receiving suppressive ART for a shorter duration than Americans (6.8 vs 9.1 years; P = .001; Table 1 ). Finally, Ugandans had lower CD4 + T-cell counts at the time of blood sampling for QVOA, which remained significantly lower than counts in Americans after controlling for nadir CD4 + T-cell count and duration of suppressive ART (cell count, 528/μL vs 662/μL, P = .04; Table 1 ). The frequency of latently infected cells in Ugandans and Americans was assessed using the QVOA, which measures the frequency of rCD4 cells able to produce infectious HIV-1 in culture after a single round of maximal T-cell activation. Ugandans had a 3-fold smaller inducible reservoir than the previously tested Americans (median reservoir size:=m 0.36 vs 1.08 IUPM, P < .001; Figure 1 ). This difference remained significant after controlling for age, sex, HIV-1 risk exposure, pre-ART plasma HIV-1 RNA level, nadir CD4 + T-cell count, duration of suppressive ART, proportion of viral loads >400 copies/mL after initial suppression, ART regimen, and CD4 + T-cell count at the time of QVOA. The adjusted difference in reservoir size between Ugandans and Americans was 0.55 log 10 IUPM (P = .04).
Clinical and demographic characteristics that may explain differences in reservoir size were also examined. In stratified analyses, reservoir size was not associated with age, sex, nadir CD4 + T-cell count, ART regimen, proportion of viral loads >400 copies/mL after initial suppression, nor CD4 + T-cell count at the time of QVOA in either population ( Table 2 ). Among Ugandans, however, reservoir size was correlated positively with viral set point (0.25 log 10 IUPM per log 10 HIV-1 RNA copies/mL; P = .01), and a similar trend was observed in Americans (0.10 log 10 IUPM per log 10 HIV-1 RNA copies/mL, P = .07; Table 2 and Figure 2A ). In addition, in both populations reservoir size correlated negatively with duration of suppressive ART (Ugandans, -0.51 log 10 IUPM/10 years [P = .02]; Americans, -0.18 log 10 IUPM/10 years [P = .04]; Table  2 and Figure 2B ). These correlations are consistent with the slow decay of the latent reservoir noted in earlier studies [6, 11, 13] . The magnitudes of these correlations (reservoir size with viral set point and also reservoir size with duration of suppressive ART) did not differ significantly between populations (P = .25 and P = .26, respectively).
DISCUSSION
Before this study, the size and clinical correlates of the latent reservoir had not been established in any cohorts from sub-Saharan Africa. We show here that the frequency of rCD4 cells latently infected with replication-competent HIV-1 was 3-fold lower in a cohort of virally suppressed individuals from Rakai, Uganda, observed in a cohort of virally suppressed individuals from Baltimore, who had been previously studied using identical outgrowth techniques [9, 10, 12] . Of note, reservoir size in the present cohort from Baltimore is similar to sizes reported in other cohorts of Americans treated during chronic infection, from San Francisco [8] and North Carolina [7, 27] . The present cross-sectional, observational study was unable to identify demographic or clinical characteristics that could account for the difference in latent reservoir size between these 2 cohorts. The reduced frequency of latently infected cells in Ugandans remained significant after controlling for age, sex, HIV exposure risk, set-point viral load, nadir CD4 + T-cell count, ART regimen, duration of viral suppression, and CD4 + T-cell count at the time of reservoir measurement. Further studies to investigate potential biological mechanisms driving the observed smaller reservoir in Ugandans are warranted. Clinical correlates of reservoir size in Ugandans were similar to those reported in American populations [6, 7, 11, 13, 14] . The frequency of latently infected cells in Ugandans correlated positively with set-point viral load and negatively with duration of viral suppression after ART initiation, suggesting that the formation of latently infected cells is dependent on viral exposure before ART, and that latently infected cells then decay slowly after ART initiation in the absence of viremia. The strengths of the associations of reservoir size with both set-point viral load and duration of suppression during ART did not differ significantly between Ugandans and Americans. One limitation of this study was its cross-sectional nature, preventing us from knowing whether diminished reservoir formation or accelerated decay explains the smaller reservoir observed in Ugandans. Documented HIV-1 seroconversion dates and longitudinal pre-ART viral load monitoring were not available for these cohorts but would allow a comparison of reservoir formation rates between populations, potentially revealing whether slower formation accounts for the decreased reservoir size in Ugandans. Longitudinal data have also proven necessary to accurately measure the decay rate in American populations [13] .
Although we observed a larger negative association between reservoir size and duration of viral suppression in Ugandans than in Americans, the associations did not differ significantly. Follow-up in this Ugandan cohort is ongoing and will help us estimate more accurately the reservoir decay rate and determine whether it differs from that reported in American populations [11, 13] . In addition, it was not possible to control for HIV-1 subtype when comparing reservoir size between these 2 cohorts, because Ugandans were infected with subtypes A and D, and Americans were infected exclusively with subtype B. However, no difference in reservoir size was observed between Ugandans infected with subtypes A versus D, which represent 2 genetically very dissimilar subtypes [28] . In contrast, HIV-1 subtypes B and D are genetically the most similar of the major subtypes, and have similar viral characteristics, such as high levels of CXCR4 usage [29] . It is therefore unlikely that infection of Americans with subtype B accounts for the difference in reservoir size compared with the Ugandan cohort, which was predominantly infected with subtype D (69%).
Finally, although multivariate regression was used to adjust for dissimilarities between the 2 cohorts (ie, sex and HIV exposure route), it is possible that residual confounding from these dissimilarities may remain and contribute to the difference in + T cells isolated from peripheral blood mononuclear cells, using the quantitative viral outgrowth assay. Multivariate regression analysis was used to assess the relationship between reservoir size and correlates; slopes and P values are adjusted for set-point viral load, duration of viral suppression with ART, and proportion of VLs >400 copies/mL after initial suppression. Abbreviations: CI, confidence interval; IUPM, infectious units per million resting CD4 + T cells.
reservoir size observed between Americans and Ugandans. For example, female sex has previously been associated with a lower viral load set point [30] [31] [32] , which we and others have shown to be associated with reservoir size. Although we did not observe any association between sex and reservoir size among Americans, we did observe a nonsignificant trend toward a smaller reservoir in Ugandan women compared with men. Further studies of the effect of sex on the latent reservoir are warranted. The QVOA remains the reference standard for quantifying the replication-competent reservoir because it measures the frequency of cells containing intact, replication-competent provirus. Alternative techniques, such as measurement of total integrated HIV-1 DNA, greatly overestimate the frequency of cells containing replication-competent virus because the vast majority of integrated HIV-1 DNA is defective, and total DNA measurements correlate poorly with measures of intact proviruses [10, 12] . However, the QVOA is based on a single round of maximum in vitro stimulation and underestimates the number of intact proviruses [10, 12] . The development of new assays to accurately enumerate intact proviruses would allow us to determine whether the differences in HIV-1 outgrowth that we observed can be attributed to differences in viral reactivation or are truly due to a lower number of intact, integrated proviruses in Ugandans.
In conclusion, this is the first reported quantification of latently infected rCD4 cells in an ART-treated, virally suppressed, sub-Saharan African population. We report a smaller reservoir in this cohort of Ugandans than previously reported in American populations. The frequency of latently infected cells in Ugandans correlated positively with set-point viral load and negatively with duration of viral suppression. The biological mechanism driving the observed smaller reservoir in Ugandans could not be identified in this study but may be of significance to HIV-1 eradication efforts.
Notes
